Latest News & Features
Biotechnology
RSB Spine files patent infringement lawsuit against competitors over spinal implant products | Plaintiff claims the defendants had knowledge of patent infringement. 31 October 2023
Americas
Biopharmaceutical patent partner leads team of technical advisors and an associate in California | Partner experienced in patent prosecution, freedom-to-operate analysis, and assessing infringement validity in the pharma and biotech industry. 26 October 2023
Big Pharma
Swiss multinational says competitor has been “uncooperative” in investigation into whether former Novartis employee took trade secrets |Novartis files complaint for discovery, asking for permission to issue subpoena. 26 October 2023
Biotechnology
The Australian government has made numerous claims for damages against patentees for savings forgone when an interlocutory/preliminary injunction delays a generic's launch but the patent is invalidated or there is a finding of non-infringement. 26 October 2023
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills. 26 October 2023
Big Pharma
International Trade Commission is to investigate 11 online pharmacies after Eli Lilly files trademark infringement complaint | The company accuses pharmacies of selling “low-grade” versions of its Mounjaro diabetes medicine. 24 October 2023
Medtech
Judges partially overturn decision that ABS had failed to prove claims in Cytonome patent were invalid | PTAB and appeals court differ in interpretation of whether claims language had single or plural meaning. 24 October 2023
Biotechnology
Amy Baker Mandragouras’ (pictured) team follow her from Cooley | New counsel’s scientific expertise is “second-to-none” | Team has experience in strategic counselling and biotech patent portfolios. 19 October 2023
Big Pharma
Luxemboug court agrees with European Commission that ‘beneficial arrangement’ between Teva and Cephalon delayed generic market entry of sleep disorder drug | Teva and subsidiary Cephalon to pay around €30m each plus costs. 19 October 2023
Americas
The firm's newest life sciences partners are patent litigators in biotech and pharma fields | Duo have secured Hatch-Waxman litigation victories. 19 October 2023